X4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 8,543 Shares of Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO David Kirske sold 8,543 shares of X4 Pharmaceuticals stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the transaction, the chief financial officer directly owned 167,750 shares in the company, valued at approximately $714,615. The trade was a 4.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

X4 Pharmaceuticals Trading Down 12.4%

X4 Pharmaceuticals stock opened at $4.09 on Thursday. The stock has a market cap of $385.77 million, a PE ratio of -0.90 and a beta of 0.35. X4 Pharmaceuticals, Inc. has a one year low of $1.35 and a one year high of $4.83. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18. The stock has a 50-day moving average of $4.09 and a two-hundred day moving average of $3.93.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $2.71 million for the quarter, compared to analyst estimates of $3.20 million. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. On average, research analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Wall Street Zen raised shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings raised X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Leerink Partners initiated coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price target for the company. Finally, Guggenheim initiated coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.38.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Empery Asset Management LP acquired a new stake in shares of X4 Pharmaceuticals in the 4th quarter valued at about $35,804,000. Bain Capital Life Sciences Investors LLC lifted its position in X4 Pharmaceuticals by 227.0% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock valued at $31,870,000 after purchasing an additional 5,530,866 shares during the period. Perceptive Advisors LLC lifted its holdings in shares of X4 Pharmaceuticals by 6.7% in the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after buying an additional 423,196 shares during the period. Kalehua Capital Management LLC acquired a new stake in X4 Pharmaceuticals in the fourth quarter valued at $14,891,000. Finally, Braidwell LP purchased a new stake in X4 Pharmaceuticals during the fourth quarter worth about $13,476,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.